BioCentury
ARTICLE | Clinical News

Avac (SRP299): Phase I trial update

February 12, 2001 8:00 AM UTC

Genesis Research and Development Corp. (NZSE/ASX:GEN), Auckland, New Zealand SR Pharma plc (LSE:SPA), London, U.K. Product: Avac (SRP299) Business: Autoimmune/Inflammation Therapeutic category: Immun...